title: Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.
abstract: BACKGROUND
  von Hippel-Lindau Disease (VHL) is an autosomal dominant inherited systemic cancer syndrome. Recently, many advances have contributed to the understanding of VHL pathophysiology.
  
  
  METHODS
  In this article we review recent developments and summarize our findings in VHL molecular pathology related to retinal and optic nerve diseases.
  
  
  RESULTS
  Loss of heterozygosity (LOH) within the VHL gene is detected in the stromal cells surrounding the capillary endothelial cells and admixed with glial cells in ocular hemangioblastomas. This finding is in line with similar findings in VHL-associated CNS hemangioblastoma and renal clear cell carcinomas. Increases of vascular endothelial growth factor (VEGF), hypoxia induced factor (HIF), and ubiquitin are found in ocular hemangioblastomas.Interestingly, tumorlet cells, which are composed of poorly differentiated small cells with prominent dark nuclei and little cytoplasm, as well as several stem cell markers, such as erythropoietin (Epo), Epo receptor (EpoR), and CD133, are present in ocular VHL lesions. CXCR4, a CXC chemokine receptor is also expressed in retinal VHL hemangioblastomas.
  
  
  CONCLUSIONS
  These findings imply that VHL cells with LOH of the tumor suppressor gene, most likely originate from a hematopoietic/vascular lineage. Targeting these proteins and ischemic factors, not VEGF alone, may be a potential therapeutic approach for VHL-associated ocular hemangioblastomas.
authors.affiliation: National Eye Institute, National Institutes of Health, Bethesda 20892-1857, USA. Chanc@nei.nih.gov
authors.forename: Chi-Chao
authors.initials: CC
authors.lastname: Chan
authors.forename: Atif Ben Daniel
authors.initials: AB
authors.lastname: Collins
authors.forename: Emily Y
authors.initials: EY
authors.lastname: Chew
mesh_terms: D016147:Genes, Tumor Suppressor / Q000502:physiology; D018325:Hemangioblastoma / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D006801:Humans; D019656:Loss of Heterozygosity; D019574:Optic Nerve Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D019572:Retinal Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics; D006623:von Hippel-Lindau Disease / Q000235:genetics / Q000473:pathology* / Q000628:therapy
chemical_list: D051794:Von Hippel-Lindau Tumor Suppressor Protein; C497446:VHL protein, human